S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY
John Mascarenhas(Tisch Hospital), Vikas Gupta(Indian Institute of Technology Kanpur), Jean‐Jacques Kiladjian(Délégation Paris 5), Francesco Passamonti(University of Milan), Moshe Talpaz(University of Michigan), Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Gabriella Hobbs(Harvard University), Gozde Colak(Morpho (United States)), Pietro Taverna, Andrea Patriarca(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), A. Chang(Morpho (United States)), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Marina Kremyanskaya(Tisch Cancer Institute), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Sandra Klein(Morpho (United States)), Srđan Verstovšek(Unknown), Timothy Devos(Rega Institute for Medical Research), Francesca Palandri(Istituto Oncologico Romagnolo), Dong Chen(Mayo Clinic in Arizona), Ronald Hoffman(Icahn School of Medicine at Mount Sinai)
Cited by 9
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k